The correction of replication errors is an essential component of genetic stability. This is clearly demonstrated in humans by the observation that mutations in mismatch repair genes lead to HNPCC (hereditary nonpolyposis colorectal cancer). This disease accounts for as many as 2-3% of colon cancers. Of these, most of them are in the two central components of mismatch repair, MLH1 (mutL homologue 1) and MSH2 (mutS homologue 2). MLH1 and MSH2 function as a complex with two other genes PMS2 and MSH6. Mismatch repair genes, and the mechanism that ensures that incorrectly paired bases are removed, are conserved from prokaryotes to human. Thus yeast can serve as a model organism for analysing mutations/polymorphisms found in human mismatch repair genes for their effect on post-replicative repair. To date, this has predominantly been accomplished by making the analogous mutations in yeast genes. However, this approach is only useful for the most highly conserved regions. Here, we discuss some of the benefits and technical difficulties involved in expressing human genes in yeast. Modelling human mismatch repair in yeast will allow the assessment of any functional effect of novel polymorphisms found in patients diagnosed with colon cancers.
Mismatch repair
The mismatch repair system serves to correct errors that occur during DNA replication. These errors can take the form of misincorporated nucleotides that result in mispaired bases or insertion/deletion loops that can result from replication slippage at polynucleotide tracts [1, 2] . The mismatch repair proteins are conserved from prokaryotes to humans. Escherichia coli uses homodimers of MutS and MutL proteins, while yeast and humans utilize multiple orthologues to each of MutS and MutL. The mismatch repair proteins function together as complexes in different combinations, each complex having activity against specific types of mismatches ( Figure 1 ). In yeast, the paralogous proteins yMlh1p and yPms1p form a heterodimer called MutLα based on one of the founding members of the family. MutLα binds with a complex of either yMsh2p and yMsh6p (MutSα) or yMsh2p and yMsh3p (MutSβ) [3, 4] . A complex of four functional proteins is required for mismatch repair activity. Equivalent proteins and complexes are present in humans except that the orthologue of yPms1p is named hPMS2 [human PMS2 (post-meiotic segregation increased 2)]. The complete MutLα-MutSα complex acts mainly to correct frameshift errors, whereas MutLα-MutSβ is predominantly involved in the removal of mispaired bases [5] (Figure 1 ). Inactivation of any of these proteins causes disruption of the mismatch repair process and therefore an increase in mutation rate or 'mutator' phenotype. As yMlh1p and yMsh2p are involved in the correction of multiple types of mismatch, deletion or mutation of these genes has a greater effect on mutation rate than the equivalent disruption of yMsh6p, which is involved in only one form of mismatch repair ( Figure 2 ).
HNPCC (hereditary non-polyposis colorectal cancer)
HNPCC is an autosomal dominant disease that accounts for as many as 2-3% of colon cancers [6, 7] . The disease is diagnosed according to the Amsterdam criteria [8, 9] , which require a presenting patient to have: (i) three or more family members with colorectal cancer, one of whom must be a first degree relative of another. (ii) The disease must have affected two or more generations. (iii) One or more affected persons must have been diagnosed while under the age of 50. HNPCC tumours are also characterized by microsatellite instability and the mutation rate at such repeat loci can be an indication of the prognosis of the disease. Furthermore, high microsatellite instability in spontaneous tumours is correlated with there being mutation or inactivation of hMLH1 [human MLH1 (mutL homologue 1)] or hMSH2 [human MSH2 (mutS homologue 2)] [10] . The Bethesda criteria build on the Amsterdam criteria, including microsatellite stability assessment, to identify colon cancer patients who should be put forward for mismatch repair gene mutation analysis [11, 12] .
HNPCC is caused by disruption of the mismatch repair pathways and most of the cases of classical HNPCC (as defined by the Amsterdam criteria) can be explained by numerous different mutations in either hMSH2 or hMLH1 sequesters yeast mismatch repair proteins but does not form a functional complex. With yeast proteins unable to function properly, mutation rate is increased. [7] . A smaller number of patients present with atypical HNPCC. hMSH2 and hMLH1 changes are also observed in atypical HNPCC but mutations in hMSH6 are much more common than in the classical form of the disease [13] . Additionally, mismatch repair defects have been associated with other cancer predisposition syndromes that include colorectal tumours. Most of the causative mutations for the Muir-Torre syndrome occur in hMSH2, and hPMS2 disruption can cause the Turcot syndrome [13] .
The discovery of a novel mutation in the mismatch repair gene of a patient can be difficult to classify as causative of colon cancer. In some cases, the change might create an The wild-type strain shows little growth on the selective medium as the baseline mutation rate is very low. All deletion strains show a mutator phenotype where individual mutation events that either restore the strain to LYS+ or confer CAN resistance are observed as distinct papillations. The variable rate of mutation between strains can be seen by comparing mlh1∆, pms1∆ and msh2∆ on LYS medium, which show high levels of mutation, with the equivalent msh6∆ patch where the papillations are much less dense. This can be explained by the fact that yMsh6p is predominantly involved in removal of mispairs rather than frameshift mutations that the lysine reversion assay measures (Figure 1a ).
obvious defect, such as a premature stop codon to give a truncated protein. However, a more subtle amino acid change can be difficult to functionally assess. Comprehensive pedigree analysis to show if the mutation segregates with the disease can suggest whether a change is pathogenic but this method is not always possible or practical. Even when large families and clinical data are available, incomplete penetrance can make pedigree analysis difficult. Using yeast as a model system for human mismatch repair could provide the first simple and accessible means by which to directly test the functional effect of polymorphisms found in patients on DNA mutation rates.
Functional assessment of mismatch repair
Quantitatively measuring the proficiency of mismatch repair in yeast is relatively simple. The short generation time of yeast and the ability to select for new mutations to auxotrophy and/or prototrophy or drug resistance means that the number of new mutants arising in a colony can be counted. Comparing the number of mutants present with the total cell population gives a mutation frequency and this can be used to calculate an accurate mutation rate [14, 15] . Commonly used assays include studying forward mutation to CAN (canavanine) resistance and mutation in homopolymeric constructs that restore prototrophy. Counting CAN R colonies assays a range of mutation types including base mismatches and frameshifts, whereas homopolymeric constructs use a run of a single base inserted into a selectable gene to assess the rate at which frameshift mutations occur [5] (Figure 2 ). Past studies of mutations found in HNPCC patients have utilized the high degree of homology between yeast and human mismatch repair genes to test the effect of these alleles on mutation rate. Selective mutagenesis of amino acid residues in yeast genes that are conserved in humans has proved most successful and has highlighted that mutations do not need to entirely inactivate the mismatch repair protein in order to have implications for increased mutation rate. In fact, point mutations can decrease mismatch repair efficiency significantly without abolishing function altogether and still lead to disease [16, 17] .
However, mutation of yeast amino acids is only useful in the most conserved domains and changing even highly conserved residues in the yeast protein may have a different effect in the human homologue. Indeed, differences between the yeast and human systems could mean that a partial reduction of mismatch repair efficiency observed in yeast may have a more severe, or even null, phenotype in humans. These differences are difficult to characterize without looking directly at the human protein.
While the mismatch repair genes are considered to have high identity between species, a mutation discovered in a patient may occur at a position not conserved between yeast and humans or the equivalent yeast base may be ambiguous, leaving us to rely on computer alignments to select the most likely candidate. Furthermore, apparently 'silent' mutations could in fact change expression levels, translation efficiency or mRNA stability. Equally, a change in amino acid does not necessarily denote a functional protein change. In some of these cases, it would be much more informative to directly test the functionality of the mutated human protein in comparison with the wild-type form.
Complementation by human genes
A step forward has been the expression in yeast of humanyeast hybrid proteins, where a section of the yeast sequence is replaced by the corresponding human region. Investigations that incorporated patient mutations have been informative as to their pathogenicity, revealing variable degrees of mismatch repair disruption [17, 18] . However, this approach may be limited as the authors found that the general efficiency of mismatch repair provided by such hybrid proteins before the introduction of mutations was inversely correlated with the length of the stretch of human sequence that was substituted into the yeast background. Therefore using humanyeast hybrid proteins may not be useful for investigation of longer human protein sequences in yeast.
An ideal solution to this problem would be to entirely replace yeast mismatch repair proteins with the relevant human homologues. However, complications arise when one considers that mismatch repair proteins act in complexes. An effort to complement an mlh1∆ yeast strain by expressing hMLH1 from cDNA on a low copy expression plasmid revealed an unexpected dominant mutator effect by expression of the human protein in wild-type yeast [19] . Any significant reduction in mutation rate shows reduced hMLH1 activity through a decrease in the dominant mutator phenotype. This effect was recently utilized to assess the consequence of 101 hMLH1 polymorphisms on mismatch repair [20] . For many of these polymorphisms, the dominant mutator phenotype was lost, suggesting that they might be pathogenic. However, the effect of other polymorphisms on the dominant mutator phenotype was not consistent with other independent estimates of pathogenicity. This inconsistency limits the utility of this approach as a diagnostic tool for new polymorphisms. The mechanism for this effect is thought to be the sequestering of yeast mismatch repair proteins by hMLH1 to form non-functional mismatch repair complexes (Figure 1c) . With the yeast proteins unable to perform normally, mutations accumulate in the same way as if one or more genes have been disrupted. To combat this interference between yeast and human proteins and ensure that effects observed in the yeast model are truly representative of the situation in humans, it seems likely that multiple gene replacements within the same strain will be necessary in order to produce functional human protein complexes within yeast.
Expression of human genes in yeast can be approached in two ways: to express human proteins from plasmids in yeast deletion strains or by replacing the yeast gene sequence with that of human to create a single copy of the human gene in the yeast genome. Expression from plasmids has the benefit of being relatively easy to achieve but has the drawback of uncontrolled expression levels. This is highly relevant to the mismatch repair system as overexpression of yMLH1p in wild-type cells causes an increase in mutation rate of a similar magnitude to inactivation of yMLH1 [21] . This effect demonstrates that expression level of even native proteins is vital to correct mismatch repair function. Control of human gene expression can be achieved by deletion of the yeast gene coding sequence and physical replacement with that of human. This will lead to a human gene that is under the control of the original yeast promoter and a human protein expressed at similar levels to the native yeast peptide.
Implications for diagnosis
As mentioned above, diagnosis of HNPCC is currently made using the Amsterdam criteria [8, 9] . Classification under such strict rules means that genetic screening of mismatch repair genes is restricted to a subset of colon cancer patients. Furthermore, the mutations that are tested for are only the most common changes seen in MSH2 and MLH1 as there has been limited investigation into the functional significance of many of the rarer mutations. Using yeast as a model system for human mismatch repair could allow the investigation and functional classification of all mismatch repair gene SNPs (single nucleotide polymorphisms) reported in patients. This could ultimately lead to a shortlist of causative SNPs that would warrant screening in all colon cancer patients. Once yeast strains expressing functional human mismatch repair complexes are created, each gene can be taken individually and the exons replaced systematically by a selectable marker to give a series of partial deletion strains (Figure 3) . Introduction of each SNP can be achieved simply by PCR of the relevant exon from genomic DNA extracted from a patient blood sample followed by transformation and homologous recombination. This allows site-specific insertion of the mutated exon to replace the selectable cassette, and the entire variant human protein will be expressed by the yeast strain. Any effect on mismatch repair can then be quantitatively measured as discussed above.
Once classed as functionally important to mismatch repair, an SNP would be added to a panel that could routinely and cheaply be screened in any patient presenting with early onset colon cancer, regardless of family history. As early diagnosis and treatment of HNPCC improves prognosis, it seems of high importance to be able to include all colon cancer patients in such screens rather than just those who fulfil the Amsterdam criteria.
